New study tracks daily life impact of rare eye disease
NCT ID NCT03295071
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 44 people with a rare inherited eye condition called Leber Hereditary Optic Neuropathy (LHON) that causes vision loss. Researchers reviewed medical records and asked participants about their vision, health, and quality of life. The goal was to better understand how the disease affects daily living and to gather information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alkek Eye Center
Houston, Texas, 77030, United States
-
CHNO Les Quinze Vingts
Paris, 75012, France
-
CHU d'Angers
Angers, 49100, France
-
Doheny Eye Center UCLA Pasadena
Pasadena, California, 91105, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Institut Catala de Retina
Barcelona, 08022, Spain
-
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
-
Moorfields Eye Hospital
London, Greater London, EC1V 2PD, United Kingdom
-
Ospedale Bellaria
Bologna, 40139, Italy
-
Ospedale San Raffaele
Milan, 20132, Italy
-
Wills Eye Institute
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could stem cells restore sight in damaged eyes?
- Gene therapy shows promise for rare eye disease that causes blindness
- Gene therapy for inherited blindness passes early safety check
- New laser device could revolutionize eye disease detection
- Can a simple blood test predict blindness before it starts?
- Gene therapy shows promise in Long-Term study for rare blindness